X
Xueyan Wang
Researcher at Pfizer
Publications - 5
Citations - 715
Xueyan Wang is an academic researcher from Pfizer. The author has contributed to research in topics: Tyrosine kinase & Receptor tyrosine kinase. The author has an hindex of 5, co-authored 5 publications receiving 676 citations.
Papers
More filters
Journal ArticleDOI
Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase.
Li Sun,Chris Liang,Sheri Shirazian,Yong Zhou,Todd W. Miller,Jean Cui,Juri Y Fukuda,Ji-Yu Chu,Asaad S. Nematalla,Xueyan Wang,Hui Chen,Anand Sistla,Tony C Luu,Flora Tang,James Wei,Cho Tang +15 more
TL;DR: 5-Fluoro-2-oxo-1, 2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide (12b or SU11248) has been found to show the best overall profile in terms of potency for the VEGF-R2 and PDGF-Rbeta tyros
Journal ArticleDOI
SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity.
Shem Patyna,A. Douglas Laird,Dirk B. Mendel,Anne-Marie O'Farrell,Christopher Liang,Huiping Guan,Tomas Vojkovsky,Stefan Vasile,Xueyan Wang,Jeffrey H. Chen,Maren Grazzini,Cheng Y. Yang,Joshua Ö. Haznedar,Juthamas Sukbuntherng,Wei-Zhu Zhong,Julie M. Cherrington,Dana D. Hu-Lowe +16 more
TL;DR: Substantial data support the ongoing phase I clinical evaluation of SU14813 in advanced malignancies, a small molecule identified from the same chemical library used to isolate sunitinib, has broad-spectrum RTK inhibitory activity through binding to and inhibition of VEGFR, PDGFR, KIT, and FLT3.
Journal Article
High Levels of HER-2 Expression Alter the Ability of Epidermal Growth Factor Receptor (EGFR) Family Tyrosine Kinase Inhibitors to Inhibit EGFR Phosphorylation in Vivo
James G. Christensen,Randall E. Schreck,Emily Chan,Xueyan Wang,Chris Yang,Luna Liu,Jean Cui,Li Sun,James Wei,Julie M. Cherrington,Dirk B. Mendel +10 more
TL;DR: It is suggested that it is more difficult to inhibit EGFR phosphorylation in vivo in cells that express high levels of HER-2, which was confirmed with ZD1839 (Iressa), a selective EGFR inhibitor that also targets the tyrosine kinase catalytic site.
Journal ArticleDOI
Rational design of 4,5-disubstituted-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-ones as a novel class of inhibitors of epidermal growth factor receptor (EGF-R) and Her2(p185erbB) tyrosine kinases
Li Sun,Jean Cui,Congxin Liang,Yong Zhou,Asaad S. Nematalla,Xueyan Wang,Hui Chen,Cho Tang,James Wei +8 more
TL;DR: A novel class of 4,5-disubstituted-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-ones has been discovered as potent and selective inhibitors of the EGF-R tyrosine kinase family.
Journal ArticleDOI
Rational Design of 4,5-Disubstituted-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-ones as a Novel Class of Inhibitors of Epidermal Growth Factor Receptor (EGF-R) and Her2(p185erbB) Tyrosine Kinases.
Li Sun,Jean Cui,Congxin Liang,Yong Zhou,Asaad S. Nematalla,Xueyan Wang,Hui Chen,Cho Tang,James Wei +8 more
TL;DR: In this paper, a novel class of 4,5-disubstituted-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-ones has been discovered as potent and selective inhibitors of the EGF-R tyrosine kinase family.